William Blair analyst Myles Minter has reiterated their bullish stance on VERV stock, giving a Buy rating yesterday.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Myles Minter has given his Buy rating due to a combination of factors including Verve Therapeutics’ promising outlook for 2025 and potential to transform shareholder value. The expected interim Phase Ib data from the Heart-2 trial of VERVE-102 and the final data from dose escalation, along with the opt-in package for Eli Lilly, are pivotal events anticipated in the second half of 2025.
In addition, Verve is viewed as an undervalued entity with significant potential to offer lifelong cholesterol and lipid control solutions through its innovative single-dose treatments. The company’s ability to address safety concerns from previous studies with its lipid nanoparticle switch for VERVE-102 and achieve notable LDL-C reductions makes it an attractive investment. Furthermore, potential penetration into growing markets and promising assets like ANGPTL3 and Lp(a) support the positive outlook and Outperform rating.
In another report released yesterday, Canaccord Genuity also maintained a Buy rating on the stock with a $32.00 price target.